Announcement PDF RNS Number : 4811T N4 Pharma PLC 16 January 2025 ​ N4 Pharma plc 16 January 2025 ("N4 Pharma" or the "Company") N4 Pharma Non-Executive Director Q&A N4 Pharma plc (AIM: N4P),the biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce the release of an investor Q&A with Dr Alastair Smith, Non-Executive Director, who recently joined the Board of the Company. The Q&A is now live on N4 Pharma's interactive investor hub here:https://investors.n4pharma.com/link/mPqEEP - Ends For more information please contact: N4 Pharma plc Nigel Theobald, Chief Executive Officer Luke Cairns, Executive Director Via N4 Pharma Investor Hub Sign up atinvestors.n4pharma.com Investor questions on this announcement We encourage all investors to share questions on this announcement via our investor hub https://investors.n4pharma.com/link/VyEJpe SP Angel CorporateFinance LLP Nominated Adviser and Joint Broker Matthew Johnson/Caroline Rowe (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) Tel: +44 (0) 20 3470 0470 Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker/James Pope Tel: +44 (0) 20 3657 0050 Northstar Communications Limited Investor Relations Sarah Hollins Tel: +44 (0) 113 730 3896 About N4 Pharma N4 Pharma is a biotech company developing Nuvec®, its proprietary gene delivery system, to enable advanced therapies for cancer and other diseases. RNA therapeutics are set to impact the treatment of a wide range of diseases and Nuvec® has several key advantages for RNA gene delivery including the ability to deliver multiple RNA therapies in a single particle, ease of manufacturing,protection of the RNA payload to allow for oral delivery, no unwanted immune response and excellent stability and storage. N4 Pharma is building out its preclinical data set and working towards first-in-human clinical data to support significant licensing deals for its Nuvec® platform with gene therapy partners. N4 Pharma's lead programme, N4 101, is an oral anti-inflammatory product for inflammatory bowel disease (IBD) which serves as a proof-of-concept programme showcasing all the benefits of the Nuvec® platform.With an estimated 10 million people globally suffering from Crohn's disease and ulcerative colitis, the IBD treatment market was worth $20.4bn in 2023 and is expected to grow by a CAGR of 3.9% to over $27.6bn by 2030, driven by both increased incidences of the disease and development of new treatments. For further information on the athttps://investors.n4pharma.com/auth/signup. Company visitwww.n4pharma.comor sign up This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NRAEASFSFSLSEFA